Evidence map›Paper›PMID 35901986›Full record

ArticleToxicology letters2022

Toxicity profiles and protective effects of antifreeze proteins from insect in mammalian models.

A Tran-Guzman, R Moradian, C Walker, H Cui, M Corpuz, I Gonzalez, C Nguyen, P Meza, X Wen, M Culty

Open access · greenAbstract read
In one paragraph

Article in Toxicology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A Tran-GuzmanDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
R MoradianDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
C WalkerDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
H CuiDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
M CorpuzDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.
I GonzalezDepartment of Chemistry and Biochemistry, California State University, Los Angeles, Los Angeles, CA, USA.
C NguyenDepartment of Chemistry and Biochemistry, California State University, Los Angeles, Los Angeles, CA, USA.
P MezaDepartment of Chemistry and Biochemistry, California State University, Los Angeles, Los Angeles, CA, USA.
X WenDepartment of Chemistry and Biochemistry, California State University, Los Angeles, Los Angeles, CA, USA.
M CultyDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA. Electronic address: culty@usc.edu.
University of Southern California · USCalifornia State University Los Angeles · US

Funding

IDENTIFICATION AND MOLECULAR BASIS FOR EFFICIENT ANTIFREEZE PROTIEN ENHANCERSSC3GM086249 · NIGMS · CALIFORNIA STATE UNIVERSITY LOS ANGELES · PI WEN, XIN · 2009 to 2023
$1.7M
NIGMS NIH HHS SC3 GM086249
6 · The paper itself

Abstract

Antifreeze proteins (AFPs), found in many cold-adapted organisms, can protect them from cold and freezing damages and have thus been considered as additional protectants in current cold tissue preservation solutions that generally include electrolytes, osmotic agents, colloids and antioxidants, to reduce the loss of tissue viability associated with cold-preservation. Due to the lack of toxicity profile studies on AFPs, their inclusion in cold preservation solutions has been a trial-and-error process limiting the development of AFPs' application in cold preservation. To assess the feasibility of translating the technology of AFPs for mammalian cell cold or cryopreservation, we determined the toxicity profile of two highly active beetle AFPs, DAFP1 and TmAFP, from Dendroides canadensis and Tenebrio molitor in this study. Toxicity was examined on a panel of representative mammalian cell lines including testicular spermatogonial stem cells and Leydig cells, macrophages, and hepatocytes. Treatments with DAFP1 and TmAFP at up to 500 μg/mL for 48 and 72 h were safe in three of the cell lines, except for a 20% decrease in spermatogonia treated with TmAFP. However, both AFPs at 500 μg/mL or below reduced hepatocyte viability by 20-40% at 48 and 72 h. At 1000 μg/mL, DAFP1 and TmAFP reduced viability in most cell lines. While spermatogonia and Leydig cell functions were not affected by 1000 μg/mL DAFP1, this treatment induced inflammatory responses in macrophages. Adding 1000 μg/mL DAFP1 to rat kidneys stored at 4 °C for 48 h protected the tissues from cold-related damage, based on tissue morphology and gene and protein expression of two markers of kidney function. However, DAFP1 and TmAFP did not prevent the adverse effects of cold on kidneys over 72 h. Overall, DAFP1 is less toxic at high dose than TmAFP, and has potential for use in tissue preservation at doses up to 500 μg/mL. However, careful consideration must be taken due to the proinflammatory potential of DAFP1 on macrophages at higher doses and the heighten susceptibility of hepatocytes to both AFPs.

Indexed as

Antifreeze ProteinsColeopteraInsect ProteinsAnimalsCryopreservationFreezingMaleRatsTenebrioAntifreeze ProteinsInsect ProteinsAntifreeze proteinsCell linesCold protectionDAFP1KidneyToxicity

Identifiers

PMID35901986
PMCPMC10174066
OpenAlexW4287733512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.